SGMO (STOCKS)
SANGAMO THERAPEUTICS INC
$0.178500
+0.008500 (+5.00%)
Prev close: $0.170000
Company Information
- Exchange
- OTC Link
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Alexander D. Macrae
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $73.95M
- Employees
- 183
- P/E (TTM)
- -0.47
- P/B (TTM)
- -3.90
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
5
Buy
3
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.08 | $0.01 | -0.0851 | -1,668.63% |
|
Dec 2025 (Q4)
|
$-0.11 | $-0.06 | -0.0488 | -79.74% |
|
Sep 2025 (Q3)
|
$-0.11 | $0.00 | -0.1102 | -55,100.00% |
|
Jun 2025 (Q2)
|
$-0.08 | $-0.13 | +0.0501 | +38.51% |
Financial Statements
| Revenues | $34.56M |
| Benefits Costs and Expenses | $158.57M |
| Costs And Expenses | $158.57M |
| Operating Expenses | $158.11M |
| Research and Development | $113.23M |
| Other Operating Expenses | $44.88M |
| Operating Income/Loss | -$123.56M |
| Income/Loss From Continuing Operations After Tax | -$123.33M |
| Income/Loss From Continuing Operations Before Tax | -$124.02M |
| Income Tax Expense/Benefit | -$687.00K |
| Net Income/Loss | -$123.33M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$123.33M |
| Net Income/Loss Available To Common Stockholders, Basic | -$123.33M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.38 |
| Diluted Earnings Per Share | -$0.38 |
| Basic Average Shares | 970,224,000 |
| Diluted Average Shares | 970,224,000 |
| Assets | $59.97M |
| Current Assets | $37.11M |
| Noncurrent Assets | $22.85M |
| Fixed Assets | $10.32M |
| Other Non-current Assets | $12.53M |
| Liabilities | $78.92M |
| Current Liabilities | $53.13M |
| Accounts Payable | $19.31M |
| Other Current Liabilities | $33.83M |
| Noncurrent Liabilities | $25.79M |
| Equity | -$18.96M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$18.96M |
| Liabilities And Equity | $59.97M |
| Net Cash Flow From Operating Activities | -$90.34M |
| Net Cash Flow From Operating Activities, Continuing | -$90.34M |
| Net Cash Flow From Investing Activities | -$16.85M |
| Net Cash Flow From Investing Activities, Continuing | -$18.13M |
| Net Cash Flow From Financing Activities | $89.31M |
| Net Cash Flow From Financing Activities, Continuing | $89.31M |
| Exchange Gains/Losses | $2.05M |
| Net Cash Flow | -$14.56M |
| Net Cash Flow, Continuing | -$16.60M |
| Comprehensive Income/Loss | -$120.32M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$120.32M |
| Other Comprehensive Income/Loss | -$120.32M |